Company news
GeoVax Labs, Inc. news in 2023
GeoVax Labs, Inc.'s news releases, calls and decks from 2023, newest first.
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
December 18, 2023
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
November 7, 2023
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
October 29, 2023
GeoVax Receives Notice of Allowance for Marburg Vaccine Patent
October 8, 2023
GeoVax Receives Notice of Allowance for HIV Vaccine Patent
October 4, 2023
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
September 25, 2023
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
September 10, 2023
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
August 28, 2023
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
August 27, 2023
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
August 9, 2023
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update
August 8, 2023
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
July 25, 2023
GeoVax Announces Issuance of Ebola Vaccine Patent
July 23, 2023
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
July 19, 2023
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
June 27, 2023
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
May 30, 2023
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
May 3, 2023
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
April 16, 2023
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
April 5, 2023
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update
March 22, 2023
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
February 14, 2023
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
February 7, 2023
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
February 6, 2023